UCB takes up rights to inflammatory diseases drug

20 March 2018

USA-based Five Prime Therapeutics (Nasdaq: FPRX), an immuno-oncology focussed biotech firm, says that UCB (Euronext Brussels: UCB) has elected to exclusively license an undisclosed drug target for inflammatory diseases.

Five Prime identified the target using its discovery platform, under a 2013 collaboration with UCB, Belgium’s largest drugmaker, which involved an upfront payment of $16 million, as well as future development, regulatory and sales-based milestones payments, and potential royalties on net sales.

Five Prime’s shares edged up 2.05% to $16.45 by close of trading on Monday, while UCB dipped 1.48% to 66.36 euros by late morning today.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK